Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the PALOMA-3 trial indicates that palbociclib plus fulvestrant significantly improves overall survival compared to placebo plus fulvestrant, with a median overall survival of 34.8 months versus 28.0 months (HR 0.81; p=0.02). This suggests a clear clinical advantage over standard care, supported by additional observational data from the Cancer Drugs Fund showing similar efficacy in real-world settings.
Cost effectiveness
The cost comparison indicates that palbociclib plus fulvestrant has similar costs to other treatments like abemaciclib and ribociclib, which supports its cost-effectiveness. The commercial arrangement further enhances its economic viability, making it a reasonable option under common thresholds.
Quality of life
The evidence suggests that palbociclib plus fulvestrant may improve health-related quality of life, particularly due to lower rates of diarrhoea compared to abemaciclib. While specific validated HRQoL measures are not detailed, the committee noted that the side effect profile could positively impact patient experience.
Supporting Domains
Safety and Adverse Effects
Palbociclib plus fulvestrant has a good safety profile, with adverse events being manageable. The committee noted that while there are some low-grade adverse events, the overall tolerability is acceptable, particularly when compared to other CDK4/6 inhibitors.
Comparator Selection
The treatment was compared against appropriate alternatives, specifically abemaciclib and ribociclib, which are also CDK4/6 inhibitors. The committee concluded that these comparators are relevant and suitable for evaluating palbociclib’s effectiveness.
Patient Population and Subgroups
The trial population in PALOMA-3 is considered broadly representative of the intended patient population, with a significant number of participants and relevant subgroup analyses. However, some differences in prior treatment history were noted.
Care Pathway Integration
Palbociclib can be integrated into existing treatment pathways with minor adjustments, as it is administered orally and does not require extensive new infrastructure or training, making it a feasible option for healthcare providers.
Resource Use and Cost Implications
The resource implications of adopting palbociclib are manageable, with the cost burden being justifiable given the expected health outcomes. The committee noted that the overall budget impact is likely to be aligned with planning.
Evidence Quality and Robustness
The evidence base is strong, primarily derived from the PALOMA-3 trial, which is a well-designed Phase III RCT. The committee also considered supportive observational data, which adds robustness to the findings.
Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term outcomes and generalizability of trial results, the context of unmet need and the supportive evidence from real-world data help mitigate these concerns.
